ANAPTYSBIO, INC. (ANAB) Gross Margin
- Gross margin · 12 months: Value (m); Formula and calculation Gross profit / revenue. Period ending 2026-06-30..
Gross margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Gross margin · 12 months | (m) | Gross profit / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Gross profit | (m) | |
| Revenue | 237.61M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Gross profit (USD) | Revenue (USD) | Cost of products and services (USD) | Gross margin |
|---|---|---|---|---|
| 2026-06-30 | (m) | $237.61M | (m) | (m) |
| 2026-03-31 | (m) | $232.39M | (m) | (m) |
| 2025-12-31 | (m) | $234.60M | (m) | (m) |
| 2025-09-30 | (m) | $169.47M | (m) | (m) |
| 2025-06-30 | (m) | $123.16M | (m) | (m) |
| 2025-03-31 | (m) | $111.87M | (m) | (m) |
| 2024-12-31 | (m) | $91.28M | (m) | (m) |
| 2024-09-30 | (m) | $57.17M | (m) | (m) |
| 2024-06-30 | (m) | $30.47M | (m) | (m) |
| 2024-03-31 | (m) | $22.96M | (m) | (m) |
| 2023-12-31 | (m) | $17.16M | (m) | (m) |
| 2023-09-30 | (m) | $14.96M | (m) | (m) |
| 2023-06-30 | (m) | $12.94M | (m) | (m) |
| 2023-03-31 | (m) | $10.69M | (m) | (m) |
| 2022-12-31 | (m) | $10.29M | (m) | (m) |
| 2022-09-30 | (m) | $4.49M | (m) | (m) |
| 2022-06-30 | (m) | $24.09M | (m) | (m) |
| 2022-03-31 | (m) | $52.90M | (m) | (m) |
| 2021-12-31 | (m) | $63.17M | (m) | (m) |
| 2021-09-30 | (m) | $122.16M | (m) | (m) |
| 2021-06-30 | (m) | $101.27M | (m) | (m) |
| 2021-03-31 | (m) | $71.25M | (m) | (m) |
| 2020-12-31 | (m) | $75.00M | (m) | (m) |
| 2020-09-30 | (m) | $18.00M | (m) | (m) |
| 2020-06-30 | (m) | $18.00M | (m) | (m) |
| 2020-03-31 | (m) | $23.00M | (m) | (m) |
| 2019-12-31 | (m) | $8.00M | (m) | (m) |
| 2019-09-30 | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | $5.00M | (m) | (m) |
| 2018-12-31 | (m) | $5.00M | (m) | (m) |
| 2018-09-30 | (m) | $8.00M | (m) | (m) |
| 2018-06-30 | (m) | $3.00M | (m) | (m) |
| 2018-03-31 | (m) | $10.00M | (m) | (m) |
| 2017-12-31 | (m) | $10.00M | (m) | (m) |
| 2017-09-30 | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $16.68M | (m) | (m) |
| 2016-09-30 | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $17.57M | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |